A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Sat0174 does abatacept increase perioperative adverse events in patients with rheumatoid arthritis compared with conventional synthetic disease modifying drugs? - a retrospective multicenter nested case-control study
2018
Saturday, 16 JUNE 2018
unpublished
cross-over group, sustained inhibition of mTSS and erosion score (ES) progression was observed during long-term treatment phase (table 1) . No effect on joint space narrowing (JSN) was observed (table 1). Overall proportions of patients with no progression (ie, mTSS change £0.5) at 36 months were 56.8% in P/Q6M, 53.3% in P/Q3M, 66.3% in Q6M group, and 65.7% in Q3M group. Incidence of adverse events (AEs), serious AEs and AEs leading to discontinuation of study drug were similar across treatment
doi:10.1136/annrheumdis-2018-eular.2469
fatcat:4akl2haajbdufam23veqvedonm